Vigonvita Life Sciences Co (HKSE:02630) Construction In Progress: HK$257.1 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02630 Vigonvita Life Sciences Co Ltd HKSE:02630
8 GF Score
Price HK$90.00
! 2 Warning Signs
View Full Analysis

What is Vigonvita Life Sciences Co Construction In Progress?

Vigonvita Life Sciences Co HKSE:02630 +5.32% 8 Construction In Progress is HK$257.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Vigonvita Life Sciences Co's quarterly construction in progress declined from Dec. 2023 (HK$279.9 Mil) to Dec. 2024 (HK$89.5 Mil) but then increased from Dec. 2024 (HK$89.5 Mil) to Dec. 2025 (HK$257.1 Mil).

Vigonvita Life Sciences Co's annual construction in progress declined from Dec. 2023 (HK$279.9 Mil) to Dec. 2024 (HK$89.5 Mil) but then increased from Dec. 2024 (HK$89.5 Mil) to Dec. 2025 (HK$257.1 Mil).

Vigonvita Life Sciences Co Construction In Progress Historical Data

* Premium members only.

The historical data trend for Vigonvita Life Sciences Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co Construction In Progress Chart

Vigonvita Life Sciences Co Annual Data
Trend Dec23 Dec24 Dec25
Construction In Progress
279.95 89.51 257.13

Vigonvita Life Sciences Co Semi-Annual Data
Dec23 Dec24 Dec25
Construction In Progress 279.95 89.51 257.13
HKSE:02630
8GF Score
Vigonvita Life Sciences Co Ltd HKSE:02630
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vigonvita Life Sciences Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$257.1 Mil mean?
Vigonvita Life Sciences Co (HKSE:02630) has a Construction In Progress of HK$257.1 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Vigonvita Life Sciences Co and its competitors.
Is Vigonvita Life Sciences Co's Construction In Progress too high?
Vigonvita Life Sciences Co's current Construction In Progress is HK$257.1 Mil. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's Construction In Progress compare to LLY and JNJ?
Vigonvita Life Sciences Co's Construction In Progress of HK$257.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Vigonvita Life Sciences Co and its competitors. Vigonvita Life Sciences Co's current Construction In Progress is HK$257.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current Construction In Progress of HK$257.1 Mil. The current Construction In Progress is HK$257.1 Mil. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current Construction In Progress is HK$257.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vigonvita Life Sciences Co Business Description

Address No. 108, Yuxin Road, 8th Floor, Building A, Suzhou Industrial Park District, Suzhou, CHN, 215123
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score

Get the complete analysis for HKSE:02630

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$90.00
Price